Serina Therapeutics (SER) Stock Overview
A biotechnology company, develops drugs to treat neurological diseases and pain. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
SER Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Serina Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.54 |
| 52 Week High | US$7.92 |
| 52 Week Low | US$1.71 |
| Beta | 0 |
| 1 Month Change | -20.87% |
| 3 Month Change | -52.17% |
| 1 Year Change | -46.64% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| SER | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 22.2% | 2.0% | 1.8% |
| 1Y | -46.6% | 27.7% | 19.4% |
Return vs Industry: SER underperformed the US Biotechs industry which returned 24.9% over the past year.
Return vs Market: SER underperformed the US Market which returned 17.3% over the past year.
Price Volatility
| SER volatility | |
|---|---|
| SER Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SER's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SER's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 13 | Steve Ledger | serinatherapeutics.com |
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial.
Serina Therapeutics, Inc. Fundamentals Summary
| SER fundamental statistics | |
|---|---|
| Market cap | US$27.94m |
| Earnings (TTM) | -US$18.80m |
| Revenue (TTM) | US$116.00k |
Is SER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SER income statement (TTM) | |
|---|---|
| Revenue | US$116.00k |
| Cost of Revenue | US$12.12m |
| Gross Profit | -US$12.00m |
| Other Expenses | US$6.80m |
| Earnings | -US$18.80m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.76 |
| Gross Margin | -10,347.41% |
| Net Profit Margin | -16,209.48% |
| Debt/Equity Ratio | 192.9% |
How did SER perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/09 17:45 |
| End of Day Share Price | 2026/01/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Serina Therapeutics, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Justin Walsh | JonesTrading Institutional Services, LLC |